Scaling Life Sciences: Philippe Pouletty on Biotech and MedTech Innovation

Philippe Pouletty, MD, co-founder of Abivax and Carvolix, says Europe must shift from being a “startup nation” to producing global leaders to survive competition from the U.S., China, and India. According to an interview with Inside Precision Medicine, Pouletty attributes Abivax’s $10 billion valuation to a strategy of merging smaller biotech firms to achieve critical mass.

Why is Europe failing to scale its life sciences companies?

European biotech firms often struggle to grow past the early stages due to a significant funding gap and less competitive capital markets. Philippe Pouletty told Inside Precision Medicine that while France is a strong starting point for engineering and management, raising more than €50 million to €60 million is frequently difficult compared to the U.S. market.

The disparity extends to public markets. Pouletty noted that the Nasdaq offers a level of competitiveness that Euronext does not. This forces many European companies to list in the U.S. to remain independent and reach commercialization. Once they do, they often transition into American companies or are acquired by large U.S. pharmaceutical firms.

Did you know? Philippe Pouletty holds one of Stanford University's highest-revenue-generating life sciences patents, highlighting the financial scale often found in U.S.-based innovation.

How does the “Abivax model” reduce biotech risk?

Most biotech companies fail because they rely on a single product candidate. Pouletty mitigated this risk at Abivax by merging two or three biotech companies after their initial R&D was complete. This approach creates a company with multiple product candidates, ensuring that a single clinical failure doesn’t bankrupt the organization.

Pouletty cited this strategy as the reason Abivax survived a Phase II failure of its most advanced drug candidate following its 2013 Euronext IPO. Because the company had other assets, it was able to continue developing a second candidate. That product eventually yielded positive Phase III results in 2025 for treating ulcerative colitis, contributing to a market capitalization of approximately $10 billion.

Comparison: Startup vs. Scale-up Goals

Pouletty contrasted the current European mindset with the necessary path to global leadership:

The “Startup Nation” Approach: Focuses on creating many small, innovative companies.
The “World Leader” Approach: Focuses on scaling companies to a size that can compete with U.S. and Chinese giants.

Will AI and robotics replace cardiovascular surgeons?

AI and autonomous robotics are designed to assist surgeons rather than replace them. Carvolix, Pouletty's current venture, combines implant technologies with AI-powered software and mini-robotics to treat stroke and heart valve disease.

According to Pouletty, the technology reduces stress for surgeons and allows them to see more patients per day. While top-tier cardiologists still provide essential expertise for complex cases, these tools allow less-experienced surgeons to perform procedures more safely. Pouletty emphasized that these systems remain under clinical supervision, allowing a doctor to take manual control at any time, similar to a pilot on an airplane.

Pro Tip: In MedTech, “agnostic” software—tools that work across different hardware brands like Medtronic or Abbott—typically sees faster adoption because it doesn’t force hospitals to switch their entire equipment ecosystem.

How does pricing affect medical R&D in the U.S. versus Europe?

The incentive for high-cost R&D differs sharply between the two regions due to reimbursement models. Pouletty explained that higher drug and device pricing in the U.S. provides the financial incentive for companies to invest in expensive research to recoup their costs.

How is Biotech changing the World? | Philippe Pouletty

In contrast, European systems prioritize universal access and lower pricing. While this ensures patients are treated regardless of their employment status, Pouletty argued it can lead to slower adoption of certain innovations. He noted that oncology drugs are often available and reimbursed in the U.S. faster than non-oncology products in Europe.

Pouletty also pointed to a failure in preventative medicine. He suggested that imaging every two years for people over 50 could catch pancreatic cancer tumors while they are still small, but the high cost of frequent MRIs prevents governments from implementing such programs.

Frequently Asked Questions

What is Carvolix?

Carvolix is a cardiovascular MedTech company co-founded by Philippe Pouletty that uses AI and autonomous mini-robotics to treat heart valve disease and stroke.

Why is the Nasdaq preferred over Euronext for biotech?

According to Philippe Pouletty, the Nasdaq is more competitive and provides better access to the capital required for biotech companies to reach the commercial stage and remain independent.

How does AI improve heart valve implantation?

AI and robotics reduce the stress on the operating surgeon, can eliminate the need for a second cardiologist in the room, and increase the number of patients a clinic can treat daily.

Join the conversation: Do you believe Europe can build a biotech ecosystem that rivals the U.S., or is the funding gap too wide to bridge? Share your thoughts in the comments below or subscribe to our newsletter for more insights into the future of medicine.